Savara
Open
$5.26
Prev. Close
$5.26
High
$5.28
Low
$5.26
Market Snapshot
$1.08B
-8.3
-0.47
70
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Savara's CFO, Dave Lowrance, has resigned, prompting a decline in stock value despite the company achieving a 138% total shareholder return over the past year.
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Recently from Cashu
FDA Extends Priority Review for Savara’s Molgramostim by Three Months Amid Amendments
Savara Pharmaceuticals, a company focused on developing therapies for rare respiratory diseases, announces that the FDA has extended the Priority Review of its Biologics License Application (BLA) for…
Savara: Pioneering Innovative Respiratory Therapies Amid Growing Healthcare Demand
Savara's Position in the Evolving Landscape of Respiratory Therapeutics Savara, a company specializing in the development of novel therapies for respiratory diseases, is well-positioned to capitalize…
Savara Advances Respiratory Therapies with Promising Progress in Pulmonary Treatments
Savara Advances in Respiratory Therapeutics Amidst Market Optimism Savara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases, continues to…
Savara Faces Class Action Lawsuit Over Alleged Securities Fraud Regarding MOLBREEVI Approval
Savara Faces Class Action Lawsuit Over Alleged Securities Fraud Savara Inc., a biopharmaceutical company focused on developing treatments for rare respiratory diseases, is embroiled in a class action…